Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-26T12:05:01.396Z Has data issue: false hasContentIssue false

Chapter 15 - Management of myelodysplasia in older adults

from Part 3 - Management of hematologic malignancies in older adults

Published online by Cambridge University Press:  05 August 2011

By
Heidi D. Klepin  and
Bayard L. Powell
Edited by
Arti Hurria  and
Harvey Jay Cohen
Arti Hurria
Affiliation:
City of Hope Cancer Center, California
Harvey Jay Cohen
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Geriatric Oncology , pp. 221 - 229
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ma, X, Does, M, Raza, A. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–1542.CrossRefGoogle ScholarPubMed
Strom, SS, Gu, Y, Gruschkus, SK. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia. 2005;19:1912–1918.CrossRefGoogle ScholarPubMed
Kantarjian, HM, Keating, MJ, Walters, RS. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4:1748–1757.CrossRefGoogle ScholarPubMed
Haase, D, Germing, U, Schanz, J. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–4395.CrossRefGoogle ScholarPubMed
Pozdnyakova, O, Miron, PM, Tang, G. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008;113:3331–3340.CrossRefGoogle Scholar
Greenberg, P, Cox, C, LeBeau, MM. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.Google ScholarPubMed
Greenberg, PL, Baer, MR, Bennett, JM. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4:58–77.Google Scholar
Bernasconi, P, Klersy, C, Boni, M. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol. 2007;137:193–205.CrossRefGoogle ScholarPubMed
Kantarjian, H, O';Brien, S, Ravandi, F. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351–1361.CrossRefGoogle Scholar
Malcovati, L, Germing, U, Kuendgen, A. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–3510.CrossRefGoogle ScholarPubMed
Cheson, BD, Bennett, JM, Kantarjian, H. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96: 3671–3674.Google Scholar
Cheson, BD, Greenberg, PL, Bennett, JM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425.CrossRefGoogle Scholar
Moyo, V, Lefebvre, P, Duh, MS. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008;87:527–536.CrossRefGoogle ScholarPubMed
Balleari, E, Rossi, E, Clavio, M. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol. 2006;85:174–180.CrossRefGoogle ScholarPubMed
Jadersten, M, Malcovati, L, Dybedal, I. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26:3607–3613.CrossRefGoogle ScholarPubMed
Negrin, RS, Stein, R, Doherty, K. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996;87:4076–4081.Google ScholarPubMed
Casadevall, N, Durieux, P, Dubois, S. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104:321–327.CrossRefGoogle ScholarPubMed
Hellstrom-Lindberg, E, Gulbrandsen, N, Lindberg, G. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037–1046.CrossRefGoogle ScholarPubMed
Jadersten, M, Montgomery, SM, Dybedal, I. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106:803–811.CrossRefGoogle ScholarPubMed
Malcovati, L, Porta, MG, Pascutto, C. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603.CrossRefGoogle ScholarPubMed
Andrews, NC.Disorders of iron metabolism. N Engl J Med. 1999;341:1986–1995.CrossRefGoogle ScholarPubMed
Bennett, JM.Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83:858–861.CrossRefGoogle ScholarPubMed
Gattermann, N.Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol. 2008;88:24–29.CrossRefGoogle ScholarPubMed
Metzgeroth, G, Dinter, D, Schultheis, B. Deferasirox in MDS patients with transfusion-caused iron overload – a phase-II study. Ann Hematol. 2009;88:301–310.CrossRefGoogle ScholarPubMed
Silverman, LR, Demakos, EP, Peterson, BL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440.CrossRefGoogle ScholarPubMed
Kornblith, AB, Herndon, JE, Silverman, LR. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441–2452.CrossRefGoogle Scholar
Fenaux, P, Mufti, GJ, Hellstrom-Lindberg, E. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.CrossRefGoogle ScholarPubMed
Kantarjian, H, Issa, JP, Rosenfeld, CS. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–1803.CrossRefGoogle ScholarPubMed
Kantarjian, H, Oki, Y, Garcia-Manero, G. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007; 109:52–57.CrossRefGoogle ScholarPubMed
Kelaidi, C, Eclache, V, Fenaux, P. The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol. 2008;140:267–278.CrossRefGoogle ScholarPubMed
List, A, Dewald, G, Bennett, J. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465.CrossRefGoogle ScholarPubMed
Estey, E, Lima, M, Tibes, R. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109:1395–1400.CrossRefGoogle Scholar
Lubbert, M, Bertz, H, Ruter, B. Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 2009;44(9):585–588.CrossRefGoogle ScholarPubMed
Brunning, R. Tumours of Hematopoietic and Lymphoid Tissues. Geneva: World Health Organization; 2008.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×